[go: up one dir, main page]

WO2008143880A3 - Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales - Google Patents

Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales Download PDF

Info

Publication number
WO2008143880A3
WO2008143880A3 PCT/US2008/006158 US2008006158W WO2008143880A3 WO 2008143880 A3 WO2008143880 A3 WO 2008143880A3 US 2008006158 W US2008006158 W US 2008006158W WO 2008143880 A3 WO2008143880 A3 WO 2008143880A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain injury
traumatic brain
bryologs
bryostatins
therapeutic effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/006158
Other languages
English (en)
Other versions
WO2008143880A2 (fr
WO2008143880A8 (fr
Inventor
Ofer Zohar
Daniel L Alkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blanchette Rockefeller Neuroscience Institute
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/068,742 external-priority patent/US9974832B2/en
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Publication of WO2008143880A2 publication Critical patent/WO2008143880A2/fr
Publication of WO2008143880A3 publication Critical patent/WO2008143880A3/fr
Publication of WO2008143880A8 publication Critical patent/WO2008143880A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte: sur l'utilisation de protéines kinases activant ou renforçant le facteur de croissance des nerf (NGF); sur le facteur tiré du cerveau (BDNF); sur d'autres facteurs neurotropes traitant les lésions traumatiques cérébrales (TBI), et spécifiquement, sur des méthodes de traitement des lésions traumatiques cérébrales comprenant les étapes suivantes: identification d'un sujet ayant subi une lésion traumatique cérébrale; administration au sujet d'une quantité efficace d'une préparation pharmaceutique comprenant un activateur de la protéine kinase C (PKC) ou de l'acide 4-méthylcatéchol acétique, dans un excipient ad hoc pour traiter au moins un symptôme de lésion traumatique cérébrale
PCT/US2008/006158 2007-05-24 2008-05-14 Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales Ceased WO2008143880A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92466207P 2007-05-24 2007-05-24
US60/924,662 2007-05-24
US12/068,742 2008-02-11
US12/068,742 US9974832B2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
PCT/US2008/001755 WO2008100449A2 (fr) 2007-02-09 2008-02-11 Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales
USPCT/US2008/001755 2008-02-11

Publications (3)

Publication Number Publication Date
WO2008143880A2 WO2008143880A2 (fr) 2008-11-27
WO2008143880A3 true WO2008143880A3 (fr) 2009-06-04
WO2008143880A8 WO2008143880A8 (fr) 2009-08-13

Family

ID=40091420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006158 Ceased WO2008143880A2 (fr) 2007-05-24 2008-05-14 Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales

Country Status (1)

Country Link
WO (1) WO2008143880A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006525A2 (fr) 2010-07-08 2012-01-12 Alkon Daniel L Activateurs de pkc et anticoagulant dans un régime pour le traitement d'un accident vasculaire cérébral
RU2470302C1 (ru) * 2011-09-21 2012-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования когнитивных нарушений в отдаленном периоде черепно-мозговой травмы
US20160025704A1 (en) * 2013-03-15 2016-01-28 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
WO2023133230A1 (fr) * 2022-01-08 2023-07-13 Sohn Joanna Monoacétyldiglycérides (plag) en tant qu'agent d'atténuation pour lésion cérébrale traumatique et lésion de reperfusion ischémique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004641A2 (fr) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Activation de la pkc utilisee pour renforcer la secretion de la sapp-a et pour ameliorer la gognition, au moyen de composes du type bryostatine
WO2004047857A1 (fr) * 2002-11-26 2004-06-10 Blanchette Rockefeller Neurosciences Institute Utilisation de fgf-18 dans le diagnostic et le traitement de troubles de la memoire
WO2006031337A2 (fr) * 2004-09-10 2006-03-23 Blanchette Rockefeller Neurosciences Institute Methode de traitement de la maladie d'alzheimer et d'amelioration cognitive
WO2008013573A1 (fr) * 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Procédés de stimulation de la croissance cellulaire, du remodelage synaptique et de la consolidation de la mémoire à long terme
WO2008100449A2 (fr) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004641A2 (fr) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Activation de la pkc utilisee pour renforcer la secretion de la sapp-a et pour ameliorer la gognition, au moyen de composes du type bryostatine
WO2004047857A1 (fr) * 2002-11-26 2004-06-10 Blanchette Rockefeller Neurosciences Institute Utilisation de fgf-18 dans le diagnostic et le traitement de troubles de la memoire
WO2006031337A2 (fr) * 2004-09-10 2006-03-23 Blanchette Rockefeller Neurosciences Institute Methode de traitement de la maladie d'alzheimer et d'amelioration cognitive
WO2008013573A1 (fr) * 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Procédés de stimulation de la croissance cellulaire, du remodelage synaptique et de la consolidation de la mémoire à long terme
WO2008100449A2 (fr) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales

Also Published As

Publication number Publication date
WO2008143880A2 (fr) 2008-11-27
WO2008143880A8 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2008100449A3 (fr) Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales
Dahmani et al. Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation
ATE418991T1 (de) Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
WO2006034373A3 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
WO2008100450A3 (fr) Effets thérapeutiques de bryostatines, de bryologues et d'autres substances apparentées sur l'altération de la mémoire induite par une ischémie/un accident vasculaire cérébral et une lésion cérébrale
WO2008143880A3 (fr) Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales
WO2006099015A3 (fr) Carotenoides, analogues de carotenoides ou derives de carotenoides permettant de traiter les troubles proliferatifs
Nori et al. Increased nerve growth factor signaling in sensory neurons of early diabetic rats is corrected by electroacupuncture
TW200621788A (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase Iε
Miyazato et al. Locus coeruleus involvement in the effects of immobilization stress on the p13 midlatency auditory evoked potential in the rat
Singewald et al. Corticotropin-releasing factor modulates basal and stress-induced excitatory amino acid release in the locus coeruleus of conscious rats
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
Koyama et al. Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
WO2005089496A3 (fr) Procédés pour le traitement de synucléinopathies
WO2005041857A3 (fr) Proteine morphogenetique (bmp) 2a de l'os et ses utilisations
Wanner et al. Muscarinic receptors within the ventromedial hypothalamic nuclei modulate metabolic rate during physical exercise
BR0316029A (pt) Combinação
BR0316021A (pt) Comibinação compreendendo um inibidor de cdk e cisplatina
WO2001082954A3 (fr) Ceruloplasmine et ses utilisations dans le cadre de troubles lies a la neurodegenerescence
DE60036382D1 (de) Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren
WO2009152415A3 (fr) Réduction d’une lésion de reperfusion myocardique par polythérapie basée sur une activation de la protéine kinase a et un blocage des récepteurs β<sb>1</sb>‑adrénergiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2